Respiratory investigation最新文献

{"title":"Relationship between idiopathic interstitial pneumonias (IIPs) and connective tissue disease-related interstitial lung disease (CTD-ILD): A narrative review","authors":"Noriyuki Enomoto","doi":"10.1016/j.resinv.2024.03.006","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.03.006","url":null,"abstract":"<div><p>While idiopathic interstitial pneumonia (IIP) centering on idiopathic pulmonary fibrosis (IPF) is the most prevalent interstitial lung disease (ILD), especially in the older adult population, connective tissue disease (CTD)-related ILD is the second most prevalent ILD. The pathogenesis of IPF is primarily fibrosis, whereas that of other ILDs, particularly CTD-ILD, is mainly inflammation. Therefore, a precise diagnosis is crucial for selecting appropriate treatments, such as antifibrotic or immunosuppressive agents. In addition, some patients with IIP have CTD-related features, such as arthritis and skin eruption, but do not meet the criteria for any CTD, this is referred to as interstitial pneumonia with autoimmune features (IPAF). IPAF is closely associated with idiopathic nonspecific interstitial pneumonia (iNSIP) and cryptogenic organizing pneumonia (COP). Furthermore, patients with iNSIP or those with NSIP with OP overlap frequently develop polymyositis/dermatomyositis after the diagnosis of IIP. Acute exacerbation of ILD, the most common cause of death, occurs more frequently in patients with IPF than in those with other ILDs. Although acute exacerbation of CTD-ILD occurs at a low rate of incidence, patients with rheumatoid arthritis, microscopic polyangiitis, or systemic sclerosis experience more acute exacerbation of CTD-ILD than those with other CTD. In this review, the features of each IIP, focusing on CTD-related signatures, are summarized, and the pathogenesis and appropriate treatments to improve the prognoses of patients with various ILDs are discussed.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An elderly woman with Birt–Hogg–Dubé syndrome having multiple pulmonary cysts mimicking lymphangioleiomyomatosis","authors":"Yasuhito Sekimoto ,&nbsp;Isao Yamawaki ,&nbsp;Chikako Iwabuchi ,&nbsp;Koichi Nishino ,&nbsp;Kazuhisa Takahashi ,&nbsp;Kuniaki Seyama","doi":"10.1016/j.resinv.2024.03.005","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.03.005","url":null,"abstract":"<div><p>The characteristics of the pulmonary cysts on the high-resolution computed tomography (HRCT) chest images are an important diagnostic clue to distinguish among cystic lung diseases. The diagnostic accuracy of HRCT was reported to be as high as 90% by experienced pulmonologists and radiologists. Herein, we report the case of an elderly woman with Birt–Hogg–Dubé syndrome (BHDS) whose HRCT images displayed lymphangioleiomyomatosis-like features of the pulmonary cysts, rendering it difficult for us to diagnose BHDS. This case illustrates the significance of a thorough anamnesis, physical examination, and skin biopsy of facial papules to establish an accurate diganosis.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140309631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional rescue of CFTR in rectal organoids from patients carrying R334W variant by CFTR modulators and PDE4 inhibitor Roflumilast","authors":"Roberta Valeria Latorre ,&nbsp;Martina Calicchia ,&nbsp;Martina Bigliardi ,&nbsp;Jessica Conti ,&nbsp;Karina Kleinfelder ,&nbsp;Paola Melotti ,&nbsp;Claudio Sorio","doi":"10.1016/j.resinv.2024.03.003","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.03.003","url":null,"abstract":"<div><h3>Background</h3><p>Many disease-causing variants in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene remain uncharacterized and untreated. Restoring the function of the impaired CFTR protein is the goal of personalized medicine, particularly in patients carrying rare CFTR variants. In this study, functional defects related to the rare R334W variant were evaluated after treatment with CFTR modulators or Roflumilast, a phosphodiesterase-4 inhibitor (PDE4i).</p></div><div><h3>Methods</h3><p>Rectal organoids from subjects with R334W/2184insA and R334W/2183AA &gt; G genotypes were used to perform the Forskolin-induced swelling (FIS) assay. Organoids were left drug-untreated or treated with modulators VX-770 (I), VX-445 (E), and VX-661 (T) mixed, and their combination (ETI). Roflumilast (R) was used alone or as a combination of I + R.</p></div><div><h3>Results</h3><p>Our data show a significant increase in FIS rate following treatment with I alone. The combined use of modulators, such as ETI, did not increase further swelling than I alone, nor in protein maturation. Treatment with R shows an increase in FIS response similar to those of I, and the combination R + I significantly increases the rescue of CFTR activity.</p></div><div><h3>Conclusions</h3><p>Equivalent I and ETI treatment efficacy was observed for both genotypes. Furthermore, significant organoid swelling was observed with combined I + R used that supports the recently published data describing a potentiating effect of only I in patients carrying the variant R334W and, at the same time, corroborating the role of strategies that include PDE4 inhibitors further to potentiate the effect of I for this variant.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212534524000455/pdfft?md5=4279dafc7c81abfb1093f615fe2ade1d&pid=1-s2.0-S2212534524000455-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140296434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endobronchial silicone spigot in prolonged air leaks: Nationwide study on outcomes and risk factors for treatment failure","authors":"Jumpei Taniguchi ,&nbsp;Shotaro Aso ,&nbsp;Jo Taisuke ,&nbsp;Hiroki Matsui ,&nbsp;Kiyohide Fushimi ,&nbsp;Hideo Yasunaga","doi":"10.1016/j.resinv.2024.03.004","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.03.004","url":null,"abstract":"<div><h3>Background</h3><p>The endobronchial silicone spigot, also known as the endobronchial Watanabe spigot, is used in bronchoscopic interventions to manage prolonged pulmonary air leakage. However, the outcomes of this procedure have not been thoroughly investigated.</p></div><div><h3>Methods</h3><p>Using a Japanese national inpatient database from April 2014 to March 2022, we assessed the clinical characteristics and outcomes of all eligible patients who received the endobronchial spigot. We also investigated risk factors associated with treatment failure. Treatment failure was defined as in-hospital death or the need for surgery after bronchial occlusion.</p></div><div><h3>Results</h3><p>We analyzed data of 1095 patients who underwent bronchial occlusion using the endobronchial spigot. Among them, 252 patients (23.0%) died during hospitalization, and 403 patients (36.8%) experienced treatment failure. Factors associated with treatment failure included age between 85 and 94 years (odds ratio [OR] 1.83; 95% confidence intervals [CI], 1.04–3.21); male sex (OR 2.43; 95% CI, 1.44–4.11); low Barthel index score; comorbidities of interstitial pneumonia (OR 1.71; 95% CI, 1.18–2.48); antibiotics treatment (OR 1.45; 95% CI, 1.02–2.07); steroids treatment (OR 1.59; 95% CI, 1.07–2.36); and surgery prior to bronchial occlusion (OR 2.08; 95% CI, 1.29–3.35). In contrast, pleurodesis after bronchial occlusion (OR 0.49; 95% CI, 0.32–0.75), and admission to high-volume hospitals were inversely associated with treatment failure (OR 0.58; 95% CI, 0.37–0.90).</p></div><div><h3>Conclusions</h3><p>The endobronchial Watanabe spigot could be a nonsurgical treatment option for patients with prolonged pulmonary air leaks. Our findings will help identify patients who may benefit from such bronchial interventions.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140191162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and causes of chronic cough in Japan","authors":"Yoshihisa Ishiura ,&nbsp;Masaki Fujimura ,&nbsp;Haruhiko Ogawa ,&nbsp;Johsuke Hara ,&nbsp;Hiromoto Shintani ,&nbsp;Soichiro Hozawa ,&nbsp;Ryo Atsuta ,&nbsp;Kensuke Fukumitsu ,&nbsp;Hideki Inoue ,&nbsp;Takanobu Shioya ,&nbsp;Masato Muraki ,&nbsp;Tokunao Amemiya ,&nbsp;Noriyuki Ohkura ,&nbsp;Yoshitaka Oribe ,&nbsp;Hiroshi Tanaka ,&nbsp;Takechiyo Yamada ,&nbsp;Mikio Toyoshima ,&nbsp;Katsuya Fujimori ,&nbsp;Tamotsu Ishizuka ,&nbsp;Manabu Kagaya ,&nbsp;Akio Niimi","doi":"10.1016/j.resinv.2024.02.017","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.02.017","url":null,"abstract":"<div><h3>Background</h3><p>Chronic cough is one of the most common symptoms of respiratory diseases and can adversely affect patients’ quality of life and interfere with social activities, resulting in a significant social burden. A survey is required to elucidate the frequency and treatment effect of chronic cough. However, clinical studies that cover all of Japan have not yet been conducted.</p></div><div><h3>Methods</h3><p>Patients who presented with a cough that lasted longer than 8 weeks and visited the respiratory clinics or hospitals affiliated with the Japan Cough Society during the 2-year study period were registered.</p></div><div><h3>Results</h3><p>A total of 379 patients were enrolled, and those who did not meet the definition of chronic cough were excluded. A total of 334 patients were analyzed: 201 patients had a single cause, and 113 patients had two or more causes. The main causative diseases were cough variant asthma in 92 patients, sinobronchial syndrome (SBS) in 36 patients, atopic cough in 31 patients, and gastroesophageal reflux (GER)-associated cough in 10 patients. The time required to treat undiagnosed patients and those with SBS was significantly longer and the treatment success rate for GER-associated cough was considerably poor.</p></div><div><h3>Conclusions</h3><p>We confirmed that the main causes of chronic cough were cough variant asthma, SBS, atopic cough, and their complications. We also showed that complicated GER-associated cough was more likely to become refractory. This is the first nationwide study in Japan of the causes and treatment effects of chronic cough.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221253452400042X/pdfft?md5=f17a6e735363aaf191b067b91aa982be&pid=1-s2.0-S221253452400042X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140190699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autopsy case: Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19","authors":"Ryoma Moriya ,&nbsp;Naoki Kamihata ,&nbsp;Yoshikazu Niwa ,&nbsp;Hisashi Kako ,&nbsp;Hideaki Takahashi ,&nbsp;Yutaro Kimura ,&nbsp;Yoshiko Shigeyasu ,&nbsp;Tetsuya Tsukamoto ,&nbsp;Naozumi Hashimoto ,&nbsp;Kazuyoshi Imaizumi","doi":"10.1016/j.resinv.2024.03.002","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.03.002","url":null,"abstract":"<div><p>A 51-year-old man with advanced lung cancer underwent chemotherapy including an immune checkpoint inhibitor (ICI). Subsequently, he developed ICI-related pneumonitis and colitis, followed by a ten-month treatment course of high doses of steroids. An infection with the SARS-CoV-2 Omicron BA.5 variant caused lethal respiratory failure. Autopsy examination revealed no evidence of viable lung cancer cells in the evaluated organs including the lungs, suggesting that pathological complete response (pCR) could be successfully achieved by ICI treatment in advanced lung cancer patients.</p><p>Recognizing steroid-resistant ICI-related adverse events as critical factors in severe COVID-19 emphasizes the need for appropriate assessment of ICI-induced pCR.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in disease burden and treatment reality in patients with severe asthma","authors":"Hiroyuki Nagase ,&nbsp;Hayato Oka ,&nbsp;Hitomi Uchimura ,&nbsp;Yoshifumi Arita ,&nbsp;Takehiro Hirai ,&nbsp;Naoyuki Makita ,&nbsp;Naoki Tashiro ,&nbsp;Kazuto Matsunaga","doi":"10.1016/j.resinv.2024.02.007","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.02.007","url":null,"abstract":"<div><h3>Background</h3><p>Biologics are clinically available for patients with severe asthma, but changes in asthma control over time are unknown. We examined changes in disease burden and treatment in severe asthma patients.</p></div><div><h3>Methods</h3><p>This retrospective study used a Japanese health insurance database (Cross Fact) and included patients aged ≥16 years treated continuously with an inhaled corticosteroid (ICS) for a diagnosis of asthma in each calendar year from 2015 to 2019. Severe asthma was defined as annual use of high-dose ICS plus one or more asthma controller medications four or more times, oral corticosteroids for ≥183 days, or biologics for ≥16 weeks. Changes in asthma exacerbations, prescriptions, and laboratory testing were examined.</p></div><div><h3>Results</h3><p>Demographic characteristics were similar throughout the study. The number and proportion of patients with severe asthma among those with asthma increased (2724; 15.3% in 2015 vs 4485; 19.0% in 2019). The proportion of severe asthma patients with two or more asthma exacerbations decreased from 24.4% to 21.5%. Odds ratios (95% confidence interval) of ≥2 asthma exacerbations in each year compared with 2015 were 0.96 (0.85–1.08) in 2016 and 0.86 (0.76–0.97) in 2017, with significant reductions observed in subsequent years. Short-acting beta agonists and oral corticosteroid prescriptions for asthma exacerbations decreased and long-acting muscarinic antagonist and biologic prescriptions for maintenance treatment increased.</p></div><div><h3>Conclusions</h3><p>This study showed improvements in disease burden and treatment in severe asthma patients. There remains an unmet medical need for patients with severe asthma, given the proportion who continue to have asthma exacerbations.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140134074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural and organizational determinants of the capacity for COVID-19 testing and diagnoses in children: Insights from the 2009 influenza and COVID-19 pandemics","authors":"Yusuke Okubo ,&nbsp;Kazuhiro Uda","doi":"10.1016/j.resinv.2024.03.001","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.03.001","url":null,"abstract":"<div><h3>Background</h3><p>This study explored factors associated with testing and diagnoses for children with COVID-19 at the hospital level and investigated whether the capacity of testing and diagnoses during the 2009 influenza pandemic was associated with that during COVID-19 pandemic.</p></div><div><h3>Methods</h3><p>In this observational study, we analyzed data obtained from the Japan Medical Data Center database, comprising 4906 medical facilities and 1.7 million infectious disease-related visits among children aged &lt;20 years in 2020–2021. Multivariable generalized linear models were used to explore determinants of testing and diagnoses capacity for COVID-19 and investigate the association between the capacity during the 2009 influenza and COVID-19 pandemics.</p></div><div><h3>Results</h3><p>Public hospitals (adjusted incidence rate ratio [aIRR], 1.52; 95%CI, 1.26–1.82) and university hospitals (aIRR, 1.44; 95%CI, 1.14–1.80) were more likely to perform testing for COVID-19 among children, compared to clinics. The highest testing rate was observed in the department of internal medicine (aIRR, 1.64; 95%CI, 1.32–2.04), followed by pediatrics (aIRR, 1.40; 95%CI, 1.10–1.78) and otolaryngology (aIRR, 1.21; 95%CI, 0.89–1.64). Cubic spline models demonstrated the dose-response relationships between testing rate for influenza in 2009 and testing rates for COVID-19. Compared to the medical facilities in the lowest quartile of testing rate for influenza in 2009, those in the highest quartile were more likely to perform testing for COVID-19 (aIRR, 1.62; 95%CI, 1.43–1.83).</p></div><div><h3>Conclusions</h3><p>Our study provides insights into the capacity of testing and diagnoses for children, highlighting the dose-response relationship between the 2009 influenza and COVID-19 pandemics, which could be valuable in preparing healthcare systems for future pandemics.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140134082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition","authors":"Masashi Bando ,&nbsp;Sakae Homma ,&nbsp;Hiroshi Date ,&nbsp;Kazuma Kishi ,&nbsp;Hiroyoshi Yamauchi ,&nbsp;Susumu Sakamoto ,&nbsp;Atsushi Miyamoto ,&nbsp;Yoshihito Goto ,&nbsp;Takeo Nakayama ,&nbsp;Arata Azuma ,&nbsp;Yasuhiro Kondoh ,&nbsp;Takeshi Johkoh ,&nbsp;Yasuhiko Nishioka ,&nbsp;Junya Fukuoka ,&nbsp;Yasunari Miyazaki ,&nbsp;Ichiro Yoshino ,&nbsp;Takafumi Suda ,&nbsp;the Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society","doi":"10.1016/j.resinv.2024.02.014","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.02.014","url":null,"abstract":"<div><p>Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with a poor prognosis and an unknown cause that generally progresses to pulmonary fibrosis and leads to irreversible tissue alteration. The \"Guidelines for the treatment of idiopathic pulmonary fibrosis 2017,\" specializing in the treatment of IPF for the first time in Japan and presenting evidence-based standard treatment methods suited to the state of affairs in Japan, was published in 2017, in line with the 2014 version of \"Formulation procedure for Minds Clinical Practice Guidelines.\"</p><p>Because new evidence had accumulated, we formulated the “Guidelines for the treatment of Idiopathic Pulmonary Fibrosis 2023 (revised 2nd edition).” While keeping the revision consistent with the ATS/ERS/JRS/ALAT IPF treatment guidelines, new clinical questions (CQs) on pulmonary hypertension were added to the chronic stage, in addition to acute exacerbation and comorbid lung cancer, which greatly affect the prognosis but are not described in the ATS/ERS/JRS/ALAT IPF guidelines. Regarding the advanced stages, we additionally created expert consensus-based advice for palliative care and lung transplantation. The number of CQs increased from 17 in the first edition to 24. It is important that these guidelines be used not only by respiratory specialists but also by general practitioners, patients, and their families; therefore, we plan to revise them appropriately in line with ever-advancing medical progress.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140123052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing region of interest selection and whole-field analysis for measurement of ciliary beat frequency in high-speed video analysis","authors":"Miki Abo ,&nbsp;Kousuke Imamura ,&nbsp;Shigekuni Hosogi ,&nbsp;Takafumi Kobayashi ,&nbsp;Yoshihiro Takeda ,&nbsp;Kazumasa Kase ,&nbsp;Hayato Koba ,&nbsp;Satoshi Watanabe ,&nbsp;Noriyuki Ohkura ,&nbsp;Johsuke Hara ,&nbsp;Seiji Yano","doi":"10.1016/j.resinv.2024.02.016","DOIUrl":"https://doi.org/10.1016/j.resinv.2024.02.016","url":null,"abstract":"<div><h3>Background</h3><p>Ciliary beat frequency (CBF) is crucial in mucociliary clearance. High-speed video analysis (HSVA) is commonly used to measure CBF but lacks standardization. We compared visual observation and computer-assisted calculation using fast Fourier transformation (FFT) in freshly collected bronchial ciliary epithelial cells and cultured cells.</p></div><div><h3>Methods</h3><p>Bronchial epithelial cells were obtained from 12 patients who required bronchoscopic examination. Eighty-five videos of ciliary movement of freshly collected and cultured cells were recorded and used to calculate CBF using manual observation, region of interest (ROI) selection, and whole-field analysis.</p></div><div><h3>Results</h3><p>CBF measured by the ROI selection method strongly correlated with that measured using manual observation, especially in freshly collected cells. However, 27.8% of the manual observation method values were doubled in the ROI selection method, probably because a round trip of cilia was calculated as two cycles and needed to be corrected to 1/2 value. Upon increasing the number of ROIs, the results of the ROI selection method came closer to that of WFA.</p></div><div><h3>Conclusions</h3><p>Computer-assisted calculation using FFT can aid in measuring CBF; however, current methods require visual confirmation. Further automated evaluation techniques are needed to establish more standardized and generalized CBF measurement methods using HSVA.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140123059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}